Search

Your search keyword '"Joos, R."' showing total 251 results

Search Constraints

Start Over You searched for: Author "Joos, R." Remove constraint Author: "Joos, R."
251 results on '"Joos, R."'

Search Results

1. Deterministic Storage and Retrieval of Telecom Quantum Dot Photons Interfaced with an Atomic Quantum Memory

2. POS0335 DECODING THE T-CELL RECEPTOR REPERTOIRE IN CHRONIC ARTHRITIS ACROSS DIFFERENT AGES, DISEASE GROUPS, AND T-CELL SUBSETS

3. OP0129 EFFECTIVENESS OF COBRA-SLIM WITH OR WITHOUT EARLY ACCESS TO A TEMPORARY 6-MONTH COURSE OF ETANERCEPT IN EARLY RA: PRIMARY OUTCOME OF THE 2-YEAR, PRAGMATIC, RANDOMISED CARERA2020 TRIAL

4. POS0672 RHEUMATOLOGISTS OVERCALL SACROILIITIS ON X-RAY AND MRI IN AXIAL SPONDYLOARTHRITIS PATIENTS: DATA FROM THE BELGIAN INFLAMMATORY ARTHRITIS AND SPONDYLITIS COHORT (BE-GIANT)

6. Development and implementation of the AIDA International Registry for patients with undifferentiated systemic autoinflammatory diseases

7. OP0216 DEVELOPMENT, REFINEMENT AND WEIGHTING OF CANDIDATE CRITERIA FOR AXIAL DISEASE IN JUVENILE SPONDYLOARTHRITIS: AN INTERNATIONAL COLLABORATION

8. POS0173 DATA-DRIVEN MRI DEFINITIONS FOR ACTIVE AND STRUCTURAL SACROILIAC JOINT LESIONS IN JUVENILE SPONDYLOARTHRITIS TYPICAL OF AXIAL DISEASE

9. International Consensus for the Dosing of Corticosteroids in Childhood-Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis

10. Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis

11. Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA

12. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16□weeks of treatment: the CareRA trial

13. O.51 - Abatacept sous-cutané chez des patients présentant une arthrite juvénile idiopathique polyarticulaire et une réponse inadéquate aux DMARDs conventionnels ou biologiques : pharmacocinétique, efficacité et sécurité

15. A148: A Multi-Center, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab in Pediatric Patients With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy: Week 48 Results

16. Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept

17. Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label 2-Year Extension of a Phase 3 Trial

19. Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data

21. Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial

22. Monitoring Lake Ontario’s waterbirds

23. Freie mitteilungen

25. Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study

26. Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy

27. Caradrina morpheus

28. Acronicta aceris

29. Haplotinea ditella

30. Aedia funesta

31. Diplopseustis perieresalis

32. Aporophyla nigra

33. Vielfalt der nachtaktiven Gross- und Kleinschmetterlinge in zwei Parkanlagen bei Basel

34. Spuleria flavicaput

35. Gortyna flavago

36. Monopis imella

37. Mythimna obsoleta

38. Mormo maura

39. Gluphisia crenata

40. Thalera fimbrialis

41. Caloptilia fribergensis

42. Apeira syringaria

43. Caloptilia hemidactylella

44. Dysgonia algira

45. Epiblema costipunctana

46. Platypergea kadenii

47. THU0598 Safety of tocilizumab in patients aged <2 years with active systemic juvenile idiopathic arthritis treated for one year

48. OP0197 Evaluation of a dosing regimen for tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis

50. Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial

Catalog

Books, media, physical & digital resources